SET2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Essential Thrombocythemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Essential Thrombocythemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- SET2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- Set-2
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- ET
- cancer_type_detailed
- Essential Thrombocythemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+1.681
- INTERFERON_ALPHA_RESPONSE+0.796
- INTERFERON_GAMMA_RESPONSE+0.627
- ALLOGRAFT_REJECTION+0.616
- MYC_TARGETS_V2+0.451
- IL6_JAK_STAT3_SIGNALING+0.444
- FATTY_ACID_METABOLISM+0.355
- COMPLEMENT+0.308
- G2M_CHECKPOINT+0.282
- PI3K_AKT_MTOR_SIGNALING+0.267
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.523
- TGF_BETA_SIGNALING-0.323
- TNFA_SIGNALING_VIA_NFKB-0.321
- NOTCH_SIGNALING-0.317
- GLYCOLYSIS-0.284
- P53_PATHWAY-0.187
- HYPOXIA-0.180
- UV_RESPONSE_DN-0.180
- HEDGEHOG_SIGNALING-0.162
- ANGIOGENESIS-0.136
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | OCIM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.796 |
| 2 | HEL_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.794 |
| 3 | HEL9217_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.783 |
| 4 | CMK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.773 |
| 5 | F36P_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.757 |
| 6 | MOLM16_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.735 |
| 7 | KU812_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.715 |
| 8 | MBCproject_0080_T2_RNA | — | D | 0.699 |
| 9 | MEG01_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.678 |
| 10 | P31FUJ_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.674 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 1.681 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.796 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.627 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.616 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.451 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.444 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.355 | Inavolisib | — uncovered |
| COMPLEMENT | 0.308 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.282 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.267 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.249 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.246 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.203 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| PEROXISOME | 0.177 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.169 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.153 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.148 | Inavolisib | — uncovered |